EP 4178560 A1 20230517 - WATER SOLUBLE PRODRUGS OF PTBA FOR USE IN HDAC INHIBITION AND ENHANCING RENAL RECOVERY FOLLOWING ACUTE KIDNEY INJURY
Title (en)
WATER SOLUBLE PRODRUGS OF PTBA FOR USE IN HDAC INHIBITION AND ENHANCING RENAL RECOVERY FOLLOWING ACUTE KIDNEY INJURY
Title (de)
WASSERLÖSLICHE PTBA-PRODRUGS ZUR VERWENDUNG BEI DER HDAC-HEMMUNG UND ZUR VERBESSERUNG DER NIERENERHOLUNG NACH AKUTER NIERENLÄSION
Title (fr)
PROMÉDICAMENTS HYDROSOLUBLES DE PTBA DESTINÉS À ÊTRE UTILISÉS DANS L'INHIBITION DE HDAC ET POUR AMÉLIORER LA RÉCUPÉRATION RÉNALE SUITE À UNE LÉSION RÉNALE AIGUË
Publication
Application
Priority
- US 202063049615 P 20200708
- US 202063112444 P 20201111
- US 2021040940 W 20210708
Abstract (en)
[origin: WO2022011174A1] Novel compounds and compositions including the same and methods of manufacturing and using the same, particularly for inhibiting HDAC or HDAC activity, and more particularly for enhancing renal recovery following acute kidney injury (AKI), preferably through HDAC inhibition.
IPC 8 full level
A61K 31/165 (2006.01); C07C 323/62 (2006.01); C07F 9/32 (2006.01)
CPC (source: EP)
A61K 31/165 (2013.01); A61P 13/00 (2018.01); C07C 53/18 (2013.01); C07C 323/52 (2013.01); C07C 323/60 (2013.01); C07D 205/12 (2013.01); C07D 207/12 (2013.01); C07D 211/46 (2013.01); C07D 211/48 (2013.01)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022011174 A1 20220113; AU 2021305330 A1 20230209; CA 3185103 A1 20220113; EP 4178560 A1 20230517; EP 4178560 A4 20240717; JP 2023533986 A 20230807; KR 20230039680 A 20230321
DOCDB simple family (application)
US 2021040940 W 20210708; AU 2021305330 A 20210708; CA 3185103 A 20210708; EP 21838077 A 20210708; JP 2023501152 A 20210708; KR 20237004440 A 20210708